The increased expression of TRAF1 subsequently contributes to the activation of downstream antiapoptotic and proangiogenic pathways in sunitinib-resistant cells, thereby promoting angiogenesis and metastasis in RCC. Here, TRAF1 is linked to renal cell carcinoma.